Carbon sorbent having antibacterial and antimycotic properties and method for production thereof
SUBSTANCE: method of producing a carbon sorbent with antibacterial and antimycotic properties includes impregnating granules of a carbon hemosorbent with 10-50% aqueous solution of glycolic acid for 7-9 hours at room temperature. The ratio of the hemosorbent to the modifier solution of glycolic acid is 1:1. Further, drying is carried out for an hour at 100-110°C. Polycondensation of glycolic acid on the carbon hemosorbent is carried out in two steps: at 185-205°C for 1 hour, at 215-235°C for not less than 5 hours, on a sand bath. The disclosed modified carbon sorbent with antibacterial and antimycotic properties is granules with a round shape, contains not less than 5% polyglycolide, characterised by a specific adsorption surface area of less than 250 m2/g and total pore volume of less than 0.50 cm3/g.
EFFECT: improved properties of the sorbent.
2 cl, 2 tbl, 2 dwg
The invention relates to a process for the production of carbon sorbents with antibacterial and antimycotic properties on the basis of porous carbon materials. Intended for use in medicine and veterinary medicine.
In connection with the environmental problems of environment and development of various infectious diseases at the present time there is an acute problem of preservation of human health. Therefore, the development of effective sorption materials with biospecific properties is still relevant. These materials can be used in the methods of sorption detoxification: hemosorption, enterosorption, application of sorption (vulnerable). It is known that carbon materials exhibit high sorption activity against pathogenic microorganisms of low and medium molecular weight and they produce toxins.
To regulate the adsorption capacity of the carbon sorbent efficiency biospecific actions sorbent requires chemical modification of its surface. As modifiers apply biocompatible non-toxic substances active against pathogenic microflora of different nature. High biospecific interaction of the developed materials with pathological proteins, cell and pathogenic microorganisms is achieved due to the properties of the functional groups of the modifier and the porous structure of the carbon sorbent.
In recent years interest has grown in polymeric materials used as modifiers. This is due to the prolonged development of drugs based on polymeric carriers [Landfester K. Miniemulsions for nanoparticle synphesis // Top Curr Chem. - 2003. - Vol.227. - P. 75-124; Magdalena Stevanovic', Ines Bracko, Marina Milenkovic Multifunctional PLGA particles containing poly(L-glutamic acid)-capped silver nanoparticles and ascorbic acid with simultaneous antioxidative and prolonged antimicrobial activity // Acta Biomaterialia 10 (2014) 151-162].
Of polymers for medical purposes receive a surgical suture, a film material as a coating on wounds and burns, non-woven materials, thermoplastic orthopedic implants, plates, screws, pins and other So-known compositions and methods for producing activated polymeric nanoparticles for targeted delivery of drugs, where the nanoparticle includes a biocompatible polymer, representing one or more polyesters selected from the group consisting of polylactic acid, polyglycolic acid, copolymer of lactic and glycolic acids, and combinations thereof (patent RF 2473331).
Glycolic acid is included in the compositions for the care of the oral cavity (RF patent 2460512) and for production of barrier coatings in the form of a carrier polymer film (patent RF 2435811). In addition, glycolic acid is an antiseptic and disinfectant (RF patent 2359704), use the tsya in cosmetology at the peel for skin rejuvenation (RF patent 2253437).
With the aim of creating new materials modification of the polysaccharide chitosan grafting of glycolic acid with its subsequent polycondensation during the heat treatment without the use of catalytic amounts of heavy metals (Bogomolov, I. B., Kozlov N. In., The Chains S. N. Modification of chitosan by inoculation of glycolic acid with its subsequent polycondensation process heat treatment // high-Molecular compounds, series B, 2009. So 51. No. 9. S. 1695-1703). These films are synthesized from a copolymer of chitosan and polyglycolic acids, are of interest for medicine as a separation membrane.
The choice of glycolic acid (GA) as a modifier due to its properties that meet the requirements of medicine: toxicity; the presence of hydroxyl groups that can react polycondensation with the formation of biologically active polymer (oligomer) with anti-inflammatory, antibacterial properties, good solubility in aqueous solutions; the close similarity in chemical composition with biopolymers (e.g. proteins).
Closest to the proposed sorbent is carbon sorbent with antibacterial properties in the form of granules, rounded form, which contains polyvinylpyrrolidone in the amount of 4.5-5.5 percent, is characterized by specific adsorption surface is less than 50 m2 3/g (RF patent 2481848, prototype)
The method of obtaining carbon sorbent with antibacterial properties includes impregnation of the granules of carbon hemosorbent solution modifier and drying of the product and differs in that the impregnation of the pellets of 0.2-1.0% solution of the initiator in N-vinyl pyrrolidone with pH 7.0 and 7.5, the residual pressure of 15-20 mm RT.article and the ratio hemosorbent:initiator solution in N-vinyl pyrrolidone 1:1,4-2,0 within 15-30 minutes with a subsequent rise of temperature of 65-75°C, holding at that temperature for 0.5-8 hours in an inert atmosphere and washed in water from the residual monomer at room temperature for 0.5-2 hours.
The aim of the invention is to develop a carbon sorbent with antibacterial and antimycotic properties.
The proposed method of obtaining carbon sorbent with antibacterial and antimycotic properties includes impregnation of the granules of carbon hemosorbent 10-50% aqueous solution of glycolic acid (filling the pore capacity, static conditions) for 7-9 hours at room temperature, the ratio hemosorbent:solution Ledger is 1:1. Then is dried for one hour at 100-110°C. the Polycondensation of glycolic acid on the carbon sorbent occurs in 2 stages: at a temperature of 185-205°C for 1 hour and at ambient temperature is re 215-235°C - not less than 5 hours.
The proposed modified carbon sorbent with antibacterial and antimycotic properties represents granules rounded, contains polyglycolide not less than 5%, is characterized by specific adsorption surface is not more than 250 m2/g and total pore volume of not more than 0,50 cm3/year
Distinctive features of this invention are:
- use as source material carbon hemosorbent developed specific adsorption surface 300-400 m2/g and a total pore volume of at least 0.4 cm3/g (Spa (scientific production Association-1);
- surface modification of carbon hemosorbent aqueous solution of glycolic acid with its subsequent polycondensation during heat treatment. The inoculation process is carried out in several stages:
- impregnation of the granules of carbon hemosorbent 10-50% aqueous solution of glycolic acid in static conditions for 7-9 hours at room temperature, the ratio hemosorbent:solution Ledger 1:1;
- drying of the sorbent impregnated with an aqueous solution of glycolic acid within one hour at 100-110°C;
- polycondensation of glycolic acid on the carbon sorbent in 2 stages: at a temperature of 185-205°C for 1 hour, at a temperature 215-235°C is not less than 5 hours on a sand bath.
The modification of the carbon GE is sorbent the proposed method modifier - glycolic acid - with its subsequent polycondensation, changes the chemical nature of the surface of the carbon matrix, and its porous structure. The results illustrating the changes of the parameters of porous structure and chemical composition of the samples of the carbon sorbent, obtained by the prototype and after inoculation with a solution of glycolic acid in accordance with examples of the present invention, are shown in table 1.
The basic textural characteristics - specific adsorption surface area, total pore volume and the pore size is determined by isothermal adsorption-desorption of nitrogen obtained with the device "Gemini 2380". The calculation of adsorption specific surface held by the BET equation.
In Fig.1(a) presents the NMR13With a range of polymer of glycolic acid in the solid phase (obtained by the spectrometer Advance-400"). Signal with a chemical shift 167 M. D. belongs to the carboxyl carbon of the polymer. The methylene carbons of the polymer absorb in the region of ~60 m D. Unresolved signal with a chemical shift of ~64 M. D. meets one of the end groups of CH2polymer, namely ONSOON. Selected conditions modification allow to obtain oligomers (hexamers) of glycolic acid.
In Fig.1(b) presents the NMR13With a range of glycolic acid after desorption with modified when Renta in contact with 0.9% NaCl for 3 hours (1) and 24 hours (2). According to the results after contact with the modified sorbent during the day into the solution becomes less than 0.1% glycolic acid (weak narrow singlet peaks in the range of 8 and 4 ppm, related to glycolic acid, on the vast and broad peak water), which proves the strong binding of the modifier (glycolic acid) in the porous structure of the sorbent.
For the studied samples obtained from thermogravimetric curves on the device DTG-60 H "Shimadzu": Fig.2(a) thermograms of unmodified sorbent; Fig.2(b) - sorbent modified glycolic acid with its subsequent polycondensation. Unlike unmodified, for a sample of sorbent modified glycolic acid with its subsequent polycondensation, there is ecoeffect in the temperature range 250-320°C. According to literature data, the presence of this peak on thermogram is explained by the decomposition and destruction of applied polymer of glycolic acid (Matthias Epple, Oliver Herzberg // J. Appl Biomater. 1998. 43. P 83-88).
Thus, the complex physico-chemical methods established that the process of modifying the carbon hemosorbent glycolic acid and subsequent polycondensation leads to the formation of polyglycolide on the carbon surface. This causes the antibacterial and antimycotic properties of the obtained carbon with the bent.
Performed stand microbiological testing of the samples modified hemosorbent in the Central research laboratories of the State budgetary institution of higher professional education of the Omsk state medical Academy of the Ministry of health and social development of the Russian Federation (bmrc AGMA).
The antibacterial properties of the samples studied in relation to the test microorganisms are gram-positive, gram-negative bacteria and to the mixture of these cultures, previously investigated for resistance to antibiotics over time.
Used in the work of gram-positive test organisms (Staphylococcus aureus, Staphylococcus aureus) and gram-negative test organisms (Pseudomonas aeruginosa, Escherichia coli; Klebsiella pneumoniae, Klebsiella pneumonia, Escherichia coli, Escherichia coli). In addition, the investigated mixture of the tested crops. All strains isolated from clinical material, antibioticresistant.
Antimycotic (antifungal) properties of the samples studied in relation to the pathogenic yeast-like fungi. Subjects fungal culture of Candida: Candida albicans and Candida krusei.
The identification of microorganisms was carried out on test systems for production PLIVA - Lachema Diagnostica (Czech Republic) in computer programs is e "MICROBE Machine".
All the studied mixtures of the tested cultures were prepared by mixing equal volumes of the prepared working concentration of microbial cells with stirring. Mixing the mixture of cultures was performed on vortex-shaker ELMI.
Working dilution for experience: bacterial cells ~103CFU (colony forming units) in 1 ml of culture Candida - 280-360 CFU in 1 ml of the Control were sown working dilutions of the tested crops.
The concentration of microbial cells was set on the device for determining the turbidity of the suspensions Densi-La-Meter (PLIVA-Lachema, Italy).
For evaluation of antibacterial action of carbon sorbents used the method of direct seeding on a nutrient medium.
Sterilization sorbents before the bench of biomedical tests carried out with saturated steam at a gauge pressure of 0.11±0.02 MPa and a temperature of (121±1)°C in the autoclave.
Example 1 (prototype)
A portion of hemosorbent mass of 1 g is impregnated with a 1.0% solution of the initiator in N-vinyl pyrrolidone in a ratio of hemosorbent:a solution of 1.0:1.5 and conduct the polymerization at a temperature of 68°C for 2 hours in an inert atmosphere, followed by washing and drying. The main characteristics of this sample are given in table.1.
For sorbent modified in this way, spend the adsorption of bacterial cells and fungal microorganism is C.
To the modified sorbent (0.5 ml) was added 1 ml of microbial suspension (test microorganisms), shaken on a vortex-shaker (to remove bubbles) and incubated overnight. Have three parallel tests for each type of microbial cells and a mixture of microorganisms (gram-positive, gram-negative bacteria, yeast-like fungi).
After this time contact of the sorbent with pathogenic culture (24 h) select the supernatant liquid in a quantity of 50 μl. Then seeded on sterile plates Petri dishes with nutrient medium GMF agar (mastopathy agar for bacteria, fungi - "Saburo".
Sown in Petri dishes with crops placed in CO2-15 ° C incubator upside down and incubated: bacteria at a temperature of 37±1°C for 24±2 hours, yeast-like fungi - 48-72 hours.
Calculation of grown colonies spend on a stencil visually in 5 fields on 1 cm2recalculated on the size of the Cup (diameter 90 mm). The result judged by the number of colony forming units (CFU) on the surface, comparing with control (concentration set on the device for the determination of turbidity). The results are expressed by the number of colony forming units (CFU) in 1 ml of the investigated samples.
Sorbent modified in this way, exhibits antibacterial activity against whom oseney to gram-positive bacteria Staphylococcus aureus at the time of contact of not less than 6 hours, to gram-negative bacteria Ps. aeruginosa, Kleb. Pneumonia - not less than 3 hours, E. Coli - not less than 6 hours, does not show antifungal properties against yeast-like fungi of the genus Candida. It is shown that after 24 hours, the number of fungi comparable with the control (table.2).
A portion of hemosorbent weighing 3 g is impregnated with a 10% aqueous solution of ha for the ratio hemosorbent: solution Ledger 1:1 for 8 hours at room temperature, then dried impregnated sorbent for 1 hour at 105°C. After drying conduct the polycondensation Ledger on the carbon sorbent in two stages: at a temperature of 195±5°C for 1 hour and at a temperature of 225±5°C for a further 5 hours on a sand bath. The main characteristics of this sample are given in table.1.
For sorbent modified in this way, spend the adsorption of bacterial cells and fungal microorganisms in example 1.
This modified carbon sorbent has an antibacterial effect against gram-positive and gram-negative monocultures and mixtures. Antibacterial action of this sample is observed after the first hour of contact with the microflora. It was found that obtained sorbent exhibits and antifungal properties against pathogenic yeast Candida: after interaction with Candida abicans at least 3 hours microbial growth on the Petri dishes were absent, with Candida krusei is not less than 1 hour (table.2).
Similar to example 2, but the impregnation is carried out in 4 hours.
Similar to example 2, but the ratio hemosorbent:solution Ledger of 1.0:0.5 in.
Similar to example 2, but the polycondensation Ledger on the carbon sorbent is carried out in one stage at a temperature of 195±5°C for 1 hour.
Similar to example 2, but the polycondensation Ledger on the carbon sorbent is carried out in one stage at a temperature of 175±5°C for 5 hours.
Analogous to example 2. The polycondensation Ledger on the carbon sorbent is carried out in two stages: at a temperature of 195±5°C for 1 hour and at a temperature of 225±5°C for a further 2 hours.
Similar to example 2, but a portion of hemosorbent impregnated with a 25% aqueous solution of ha.
Similar to example 2, but a portion of hemosorbent impregnated with a 50% aqueous solution of ha.
As follows from the examples and tables, the carbon sorbent modified glycolic acid and subsequent polycondensation, has an antibacterial effect against gram-positive and gram-negative monocultures, their mixtures. Antibacterial action of this sample is observed after the first hour of contact with the microflora. The first set of antimycotic properties of carbon sorbent modified Glick is left acid and subsequent polycondensation, in relation to antibiotic resistant strains of pathogenic yeast-like fungi of the genus Candida: Candida albicans and Candida krusei.
Thus, a method of modifying carbon sorbent allows to obtain materials, manifesting not only antibacterial, and antifungal properties. The proposed carbon sorbent is of interest for the sorption of medicine in the treatment of diseases: fungal sepsis (as hemosorbent); fungal infection of the gastrointestinal tract (as enterosorbent); purulent-septic diseases associated with the accumulation of pathogenic cultures in obstetrics and gynecology (as applicators).
1. The method of obtaining carbon sorbent with antibacterial and antimycotic properties, including impregnation of the granules of carbon hemosorbent solution modifier, characterized in that conduct impregnation 10-50% aqueous solution of glycolic acid for 7-9 hours at a ratio of hemosorbent:the solution of glycolic acid 1:1, drying the impregnated sorbent and polycondensation of glycolic acid on the carbon sorbent at a temperature 185-205°C for 1 hour, then at a temperature of 215-235°C for at least 5 hours.
2. Carbon sorbent with antibacterial and antimycotic properties is in the form of granules rounded, characterized in that the method under item 1, contains polyglycolide not less than 5%, is characterized by specific adsorption surface is not more than 250 m2/g and total pore volume of not more than 0,50 cm3/,
SUBSTANCE: invention relates to antifungal compounds based on 3,5,8-trioxabicyclo[5,1,0]octane derivatives, obtained by trans-opening of its epoxide cycle, namely 6-(arylthio)-1,3-dioxepan-5-ols in racemic and enantiopure form of the general formula Ia and Ib , where at R1=F, R2=H, R3=H; at R1=Br, R2=H, R3=H; at R1=H, R2=Br, R3=H; at R1=H, R2=H, R3=Br.
EFFECT: compounds of formula Ia and Ib possess low toxicity and high antifungal activity with respect to fungi Candida albicans, Aspergillus fumigatus, Epidermophyton floccosum, Mucor pusilos, Saccharomyces cerevisiae and can be applied in medicine and veterinary.
2 tbl, 13 ex
SUBSTANCE: as an active substance, the composition contains butoconazol, a base that is a combination of a hydrophobic ingredient, a hydrophilic ingredient and an emulsifier, and also a gel-forming polymer. Hydroxypropylstarch phosphate is preferentially used as the gel-forming polymer. A method for preparing the declared composition consists in the fact that a mixture of butoconazol with a portion of the hydrophilic ingredient, the hydrophobic ingredient and emulsifier is added with a dispersion of the gel-forming polymer in the rest of the hydrophilic ingredient; the produced mixture is agitated homogenously with a preserving agent added where it might be necessary.
EFFECT: new pharmaceutical composition is characterised by a high level of antifungal activity, stability both at a storage temperature, and at a use temperature, and good pack extrusion.
14 cl, 2 tbl, 10 ex
SUBSTANCE: invention represents an antifungal preparation in suppositories for children containing recombinant human interferon 2α and fluconazole, wherein lysozyme, Licopid and dimephosphone are additionally introduced.
EFFECT: preparation possesses the high clinical effectiveness in the fungal diseases in children that leads to reducing the length of treatment and prolonging the intercurrent period.
1 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to the field of medicine, namely to pharmacology, and describes a composition, containing fulvic acid or its salt and an antifungal compound, selected from fluconazole and amphotericin B. In accordance with the first version of the implementation the composition contains about 10 ml/kg of a solution of from about 0.25% to about 1% (wt/vol) fulvic acid or its salt and of about 10 mg/kg fluconazole. In accordance with the second version of the implementation the composition contains 0.25% (wt/vol) of the solution of fulvic acid or its salt and from about 0.06 mg/l to about 0.5 mg/l of amphotericin B.
EFFECT: invention can be used in a method of treating a fungal infection of the human or animal body, the method includes the introduction to an object, requiring it, of a therapeutically effective quantity of the composition.
11 cl, 1 dwg, 10 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: declared group of inventions refers to veterinary science and is applicable for treating the animals suffering from bacteriosis and yeast mycosis. A declared preparation contains oxytetracycline hydrochloride, sulphadimine, ampicillin sodium, nistatine, a solvent and the active substance conduit dimethyl sulphoxide, the quick-relief anaesthetic lidocaine in the following proportions, wt %: ampicillin sodium 4.0-8.0, oxytetracycline hydrochloride 2.0-4.0, nistatine 1.0-2.0, sulphadimine 2.0-4.0, novocaine 0.25-0.5, lidocaine 0.25-0.5, dimethyl sulphoxide 10.0-20.0, 1,2-propylene glycol - the rest. A method of treating the animals consists in administering the declared preparation in a dose of 0.1-0.2 cm3 per 1 kg of body weight.
EFFECT: using the declared group of inventions is high-efficiency for treating the animals suffering from bacteriosis and yeast mycosis and enables improving livestock farms with an unfavourable incidence of bacteriosis and yeast mycosis.
5 cl, 9 ex
SUBSTANCE: preparation can be applied for elimination of fungi and in treatment of diseases, caused by fungi, as well as for the prevention of damage by fungi to different materials and agricultural products. The fungicidal preparation represents an associate of 5-[3,5-dichloro-2-hydroxybenzylidine)amino]-4-hydroxy-1H-pyrimidine-2-one with 1,2,3,4,5-pentahydroxy-6-methylaminohexane and corresponds to the following formula: . Compounds were obtained in the crystalline form, and their structure is proved by spectra of proton magnetic resonance in dimethylsulphoxide.
EFFECT: preparation has a wide spectrum of action and high solubility, which increases efficiency of its application in the form of solutions.
2 tbl, 6 ex
SUBSTANCE: invention relates to compositions and polymeric materials for biomedical use, comprising silver nanoparticles (0.0005-0.02 wt %) stabilised by amphiphilic copolymers of maleic acid (0.0008-0.05 wt %), low molecular weight organic amines (0.0002-0.04 wt %) and water. In addition, the said composition may additionally comprise the polymeric structure-forming agent.
EFFECT: introduction to the composition of the polymer structure-forming agent enables to obtain the macroporous structured hydrogel materials having prolonged bactericidal and antifungal action.
3 cl, 2 tbl, 9 ex
SUBSTANCE: invention refers to a composition containing encapsulated triterpenic acid: betulinic acid, ursolic acid or derivatives thereof in the form of salts and esters, or triterpene alcohol - betulin, which may be used in medicine for treating and preventing viral infections caused by DNA and RNA-containing viruses, such as influenza viruses, oncogenic viruses, herpes virus, herpes zoster virus, as well as infections caused by gram-positive and gram-negative bacteria: Staphylococcus spp., Streptococcus spp., Enterococcus spp., Shigella spp., Escherichia spp., Salmonella spp., Proteus spp., Acinetobacter spp., Citrobacter spp., Pseudomonas spp., Serratia spp., Klebsiella spp., Antracoides spp., Cryptococcus spp., pathogenic fungi of the genus Microsporum, Trichophyton, Nocardia, Aspergillus, yeast-like fungi of the genus Candida, including multiresistant strains, as well as Actinomycetes and some pathogenic protozoa: Entamoeba histolytica, Trichomonas vaginalis. The invention presents the composition containing an active ingredient presented by 0.5 wt % of betulin or 0.5 wt % of encapsulated triterpenic acid: betulinic acid, ursolic acid or derivatives thereof in the form of salts and esters and others, and carriers presented by: β-cyclodextrins, fullerene, lecithins and polymers binding to the ingredients to form ingredient-carrier complexes, and excipients.
EFFECT: higher efficacy of using the composition.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical industry, namely to homeopathic suppositories for treatment of fungal colpitis, vulvovaginitis, endometriosis, papillomas, cervical erosion, candidosis and vaginal dryness (versions). Homeopathic suppositories for treatment of fungal colpitis, vulvovaginitis, endometriosis, papillomas, cervical erosion, candidosis and vaginal dryness, contain Sea buckthorn oil, homeopathic oil extract, thuya oil, melaleuca oil, juniper oil, homeopathic essence of eucalyptus, homeopathic essence of elder flower, homeopathic essence of wormwood, thick extract of galium, thick extract of cimicifuga, base, taken in specified quantity. Homeopathic suppositories for treatment of fungal colpitis, vulvovaginitis, endometriosis, papillomas, cervical erosion, candidosis and vaginal dryness, containing Sea buckthorn oil, homeopathic oil extract, valerian oil, Melissa oil, Humulus lupulus oil, homeopathic essence of Viscum album, homeopathic essence of jaborandi, thick extract of galium, thick extract of cimicifuga, base, taken in specifies quantity. Homeopathic suppositories for treatment of fungal colpitis, vulvovaginitis, endometriosis, papillomas, cervical erosion, candidosis and vaginal dryness, containing homeopathic oil extract, beggar-ticks oil, homeopathic essence of lycopodium, homeopathic essence of cantharis, thick extract of galium, thick extract of cimicifuga, base, taken in specified quantity.
EFFECT: suppositories are efficient for treatment of fungal colpitis, vulvovaginitis, endometriosis, papillomas, cervical erosion, candidosis and vaginal dryness.
3 cl, 5 ex
SUBSTANCE: invention relates to use of 2-nitroheterylthiocyanates, particularly 4-rhodano-5-nitropyrimidine and 2-rhodano-3-nitripyridine derivatives of general formula (I), optionally in crystalline form or in form of pharmaceutically acceptable addition salts thereof with acids or bases, having activity on fungal strains, fungal infection agents, for producing pharmaceutical compositions that are suitable for local application. The compounds are also active on strains that are resistant to existing drugs. In general formula (I) X=N or C-R3, R1 denotes a proton, a saturated or unsaturated linear alkoxy radical having 1-5 carbon atoms; a cycloalkyloxy radical having up to 6 carbon atoms; a saturated linear alkylmercapto radical having 1-3 carbon atoms; an amino radical having 1-10 carbon atoms, selected from a saturated or unsaturated linear mono- or dialkylamino radical or a cycloalkylamino radical, cyclic amino radical. Each of the cyclic groups can be substituted with 1-2 methyl groups, or a benzylamino group; R2 denotes a proton, a saturated or unsaturated linear alkyl radical having 1-5 carbon atoms, or a cyclic aliphatic radical having up to 6 carbon atoms, trifluoromethyl, styryl or methylmercapto group; R3 denotes a trifluoromethyl, formyl, acetyl, nitro, benzoyl, cyano group or an alkoxycarbonyl substitute having 1-3 carbon atoms in the alkoxy group.
EFFECT: improved properties of compounds.
5 cl, 3 tbl, 21 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to compounds of formula and their pharmaceutically acceptable salts possessing antibacterial properties, as well as to a based pharmaceutical composition. In formula (I) R1 represents an alkoxy group; each of U and V represents CH, and W represents N, or U represents N, V represents CH and W represents CH or N, or each of U and V represents N, and W represents CH; R2 represents hydrogen or fluorine, if W represents CH, or R2 represents hydrogen, if W represents N; A represents O or CH2; Y represents CH or N; Q represents O or S; and n represents 0 or 1.
EFFECT: preparing the pharmaceutically acceptable salts possessing the antibacterial properties.
23 cl, 3 tbl, 15 ex
SUBSTANCE: invention refers to medicine, namely to surgery, and concerns preventing the abdominal adhesion formation following the intra-abdominal operations. To this effect, a laparotomic wound closure is preceded by administering Miramistin 3 ml/kg of body weight into the abdominal cavity. The preparation is left in the abdominal cavity for 5 hours and passively evacuated.
EFFECT: preparation dose schedule provides the effective prevention of the adhesion formation by the antiadhesive, antiseptic and microcirculation improving action of Miramistin.
FIELD: veterinary medicine.
SUBSTANCE: method comprises administering a mixture of medicinal solution of formaldehyde and isotonic solution of sodium chloride at a ratio by weight of (2-6):(994-998). The mixture is administered intramuscularly at a dose of 5-6 ml 6 times. The second injection is administered on the day 7-8 after the first injection, the third - on the day 7-8 after the second injection, the fourth - 12 hours after the third, the fifth - 12 hours after the fourth, the sixth - 7-8 days after the fifth injection.
EFFECT: method is highly effective in treatment of brucellosis of cattle.
3 tbl, 3 ex
SUBSTANCE: present invention relates to a preparation which inhibits microbial growth, which includes an arylamide compound as an active compound and kleptose or captisol.
EFFECT: methods of producing the preparation, use and method of treating microbial infections are disclosed.
21 cl, 5 dwg, 11 tbl, 16 ex
FIELD: veterinary medicine.
SUBSTANCE: pharmaceutical composition in the form of ointments for treatment of mastitis in cows comprises n-tetradecyltributylphosphonium bromide as active ingredient and petrolatum as an excipient at the ratio of 1:2000.
EFFECT: invention provides a pharmaceutical composition in the form of an ointment, which is new in mechanism of action, effective when applied topically at low therapeutic concentration.
SUBSTANCE: invention relates to novel hexasubstituted para-aminophenols: where R=C6H5, C6H4Cl, C6H4Br, C6H4CH3, with arylamide groups in 2,6 positions with respect to hydroxyl, which demonstrate antibacterial activity.
EFFECT: hexasubstituted para-aminophenols with arylamide groups in 2,6 positions with respect to hydroxyl, possessing high bactericidal and bacteriostatic activity.
1 tbl, 4 ex
SUBSTANCE: invention relates to veterinary, in particular to obstetrics, gynecology and reproduction biotechnology, and can be used for treating animals in case of clinical mastitis. Medication for treating animals with clinical mastitis includes: trivit - 10.0 ml, cefotaximum - 750 mg, prednisolone - 10.0 mg, nystatin - 325.0 ml. Medication is introduced to ill animals intracycternally in dose 10.0 ml with interval 12 hours after milking.
EFFECT: invention provides increased efficiency of treating clinical mastitis by complex impact on all sides of pathological process.
4 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, more specifically to new dosage forms of cephem compounds effective for treating bacterial infections.
EFFECT: dosage forms are stable; they show the improved solubility and are especially applicable for parenteral administration.
9 cl, 29 tbl, 8 ex
SUBSTANCE: invention relates to field of veterinary and is intended for treatment and prevention of postpartum acute mastitis in cows. Medication contains antimicrobial, anti-inflammatory preparations and distilled water. Medication additionally contains licorice root. As antimicrobial preparation it contains metronidazole. as anti-inflammatory preparation it contains ciprofloxacin, with the following component ratio, g/l: licorice root 80-85 g; metronidazole 3.5-4.0 g; ciprofloxacin 2.0-2.5 g; distilled water - the remaining part.
EFFECT: application of claimed medication provides expressed antimicrobial and anti-inflammatory effect with simultaneous reduction of organism's response to histamine, release of spasm of smooth muscles and reduction of permeability of capillaries.
4 tbl, 10 ex
SUBSTANCE: method involves prescribing proton pump inhibitor with one antibiotic in a dual therapy and with two antibiotics with a triple therapy twice a day within the course of 7-10 days. Helicobacter is eradicated by the separate administration of drugs. The proton pump inhibitor (omeprazole or pantoprazole) is administered two hours before the antibiotic in the dual therapy and four hours before the second antibiotic in the triple therapy. The drugs are taken for the second time 12 hours after the first one. The antibiotics (clarithromycin, amoxicillin or fromilid) are taken with water 250ml.
EFFECT: invention enables providing the more effective eradication of Helicobacter by the exposure of total therapeutic bioavailability of each preparation with underlying permanent gastric alkaline environment.
2 cl, 3 ex
SUBSTANCE: method of modifying a carbon hemosorbent includes impregnating granules with an amino acid solution, filtering, drying, holding in an inert medium and drying the obtained product. The amino acid used is arginine in the form of an aqueous solution with concentration of 10-15%. Impregnation, filtration and drying of the granules are carried out twice. Impregnation is carried out with ratio of hemosorbent to arginine solution of 1:2-5. Holding is carried out in a stream of inert gas at 150-200°C.
EFFECT: invention enables to obtain a sorbent having high selectivity with respect to high-molecular weight protein compounds of basic nature.
2 tbl, 5 ex